Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency

"Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency." Amyloid, 26(4), pp. 255–256

Disclosure statement

The authors report no conflicts of interest.

Additional information

Funding

The authors thank the patients and their families. Institutional research funding was provided by the National Natural Science Foundation of China [Grant No. 81570195, for LJ], Beijing Natural Science Foundation [Grant No. 7182128, for LJ], Foundation for Distinguished Young Physician of Peking Union Medical College Hospital [Grant No. JQ201501, for LJ], the CAMS Innovation Fund for Medical Sciences [Grant No. 2016-12M-1–002, for LJ], and The National Key Research and Development Program of China [Grant No. 2016YFC0901503, for LJ], the Capital Health Research and Development of Special Fund [Grant No.2018–2-4015], and the Fundamental Research Funds for the Central Universities, the Young Scientific Research Fund of PUMC [Grant No. 2017320004, for CX].